The biotechnology industry is becoming increasingly global, but access to capital remains highly uneven. While breakthrough therapies are being developed worldwide, companies in a handful of regions control most of the funding needed to acquire innovative startups, expand pipelines, and accelerate commercialization.
In recent years, mergers and acquisitions (M&A) have become one of the fastest ways for biotechnology companies to strengthen their portfolios. However, the ability to acquire promising businesses depends largely on how much capital companies can raise. Today, North America dominates biotech financing, Europe remains a strong but distant second, and Asia-Pacific is rapidly closing the gap through government-backed innovation programs.
North America Raises Nearly 70% of Global Biotechnology Capital
North America continues to dominate biotechnology financing by a significant margin.
Industry funding reports show that biotechnology acquirers headquartered in the United States and Canada account for approximately 65–70% of all global biotech funds raised, making the region the world’s largest source of acquisition capital.
The United States is the primary driver of this leadership. In 2024, U.S. biotechnology companies raised more than US$30 billion through public offerings, follow-on financings, venture capital, and private investments. Venture funding alone exceeded US$12 billion across hundreds of biotech startups.
Government investment also plays a major role.
The National Institutes of Health (NIH) received an annual budget of approximately US$48 billion, making it the world’s largest public biomedical research funder. This funding supports more than 300,000 researchers and nearly 2,500 universities, hospitals, and research institutions, creating a steady pipeline of technologies that later become acquisition targets.
Large pharmaceutical companies headquartered in North America also continue spending aggressively on acquisitions.
Whether you’re looking for regional insights, detailed segments, competitor analysis, or market trends, our experts provide customized sample reports for FREE; Download Now: https://www.towardshealthcare.com/download-sample/5034
Major North American Biotechnology Acquirers
| Company | Recent M&A or Investment Highlights |
|---|---|
| Pfizer | Acquired Seagen for US$43 billion to strengthen its oncology portfolio. |
| Johnson & Johnson | Acquired Shockwave Medical for US$13.1 billion in 2024. |
| Amgen | Purchased Horizon Therapeutics for US$27.8 billion. |
| Gilead Sciences | Acquired CymaBay Therapeutics for US$4.3 billion. |
| AbbVie | Acquired Cerevel Therapeutics for US$8.7 billion to expand neuroscience. |
| Merck & Co. | Continues investing billions annually in licensing and oncology acquisitions. |
These acquisitions demonstrate the financial strength available to North American buyers, allowing them to compete globally for innovative biotechnology assets.
Europe Holds Around One-Fifth of Global Biotechnology Funding
Europe has established itself as the world’s second-largest biotechnology investment hub.
Biotechnology acquirers headquartered across the United Kingdom, Germany, Switzerland, France, Denmark, Belgium, and the Netherlands collectively account for 18–22% of global biotechnology funding.
Although European companies consistently produce world-class scientific discoveries, funding rounds are generally smaller than those in the United States due to a more conservative venture capital environment.
Public investment remains substantial.
The European Union’s Horizon Europe programme has committed €93.5 billion (2021–2027) to research and innovation, including biotechnology, precision medicine, advanced therapeutics, and genomics.
The European Investment Bank (EIB) has also invested billions of euros into life sciences companies through loans and innovation financing.
Leading European Biotechnology Acquirers
| Company | Key Statistics |
|---|---|
| Roche (Switzerland) | Invests over CHF 13 billion annually in R&D and regularly acquires biotechnology companies. |
| Novartis (Switzerland) | Annual R&D spending exceeds US$11 billion, with frequent strategic acquisitions. |
| AstraZeneca (UK) | Invested approximately US$13.6 billion in R&D during 2024. |
| Novo Nordisk (Denmark) | Market capitalization exceeded US$500 billion during 2024, supporting major licensing and acquisition activities. |
| Sanofi (France) | Completed the acquisition of Inhibrx for up to US$2.2 billion. |
Europe continues producing globally competitive biotechnology companies, particularly in oncology, rare diseases, vaccines, and metabolic disorders.
Asia-Pacific Is Emerging as the Fastest-Growing Biotechnology Investment Region
Asia-Pacific is rapidly transforming into a major biotechnology powerhouse.
Although biotechnology acquirers currently account for 10–15% of global capital raised, the region has recorded the fastest investment growth over the past decade.
China has invested heavily in biotechnology through national innovation strategies, while Japan, South Korea, Singapore, and Australia continue expanding life sciences funding.
China alone now hosts more than 5,000 biotechnology companies, and its pharmaceutical market has become the world’s second largest.
Japan continues supporting regenerative medicine through accelerated approval pathways, while South Korea has committed billions of dollars to becoming a global biotechnology manufacturing hub.
Major Asia-Pacific Biotechnology Acquirers
| Company | Key Statistics |
|---|---|
| WuXi AppTec (China) | Serves over 6,000 customers across 30+ countries with annual revenue exceeding US$5 billion. |
| BeiGene (China) | Invests billions in oncology R&D and operates globally. |
| Samsung Biologics (South Korea) | World’s largest biologics CDMO with manufacturing capacity exceeding 780,000 liters. |
| Takeda Pharmaceutical (Japan) | Annual revenue exceeds US$30 billion and remains active in strategic acquisitions. |
| SK Bioscience (South Korea) | Expanded vaccine manufacturing through significant government-backed investments. |
Many Asian biotechnology companies are increasingly acquiring overseas technologies rather than relying solely on licensing partnerships.
Regional Comparison of Biotechnology Funding
| Region | Estimated Share of Global Funds Raised | Key Drivers |
|---|---|---|
| North America | 65–70% | Deep venture capital markets, active IPO ecosystem, large pharmaceutical buyers |
| Europe | 18–22% | Strong scientific research, EU innovation funding, pharmaceutical partnerships |
| Asia-Pacific | 10–15% | Government investment, manufacturing expansion, growing private capital |
| Rest of World | 2–5% | Emerging biotechnology ecosystems and regional innovation programs |
Why Is the Funding Gap So Large?
The regional imbalance is driven by several structural advantages.
The United States has the world’s largest venture capital ecosystem, biotechnology-focused investment funds, and highly liquid stock exchanges such as NASDAQ, enabling companies to raise billions quickly through IPOs and secondary offerings.
Europe produces exceptional science but typically sees lower private investment per company, leading many startups to partner with or be acquired by larger pharmaceutical firms.
Asia-Pacific benefits from strong government support, lower manufacturing costs, and expanding domestic healthcare markets, but its venture capital ecosystem is still maturing compared with North America.
Government Funding Continues to Fuel Future Acquisitions
Public investment remains one of the strongest catalysts for biotechnology growth.
The NIH’s US$48 billion annual budget continues to generate discoveries that later become commercial assets. The European Union’s €93.5 billion Horizon Europe programme supports translational research and innovation, while China, Japan, South Korea, Singapore, and Australia are investing billions in biotechnology infrastructure, manufacturing, and precision medicine.
These investments reduce scientific risk, encourage commercialization, and create a larger pipeline of companies that become acquisition targets.
Looking Ahead
Biotechnology acquisitions are expected to remain strong as companies race to secure innovative assets in oncology, gene therapy, rare diseases, obesity, immunology, and precision medicine.
North America is likely to maintain its leadership because of unmatched access to capital and institutional investors. Europe will continue leveraging scientific excellence and pharmaceutical partnerships, while Asia-Pacific is expected to deliver the fastest funding growth as governments and private investors accelerate investments.
The regional funding gap remains wide today, but increasing investment across Europe and Asia suggests that the global biotechnology acquisition landscape will become more competitive over the coming decade.
We help decision makers navigate the biotech industry with real-time market insights, company strategies, regulatory updates, and competitive intelligence – all in one easy-to-use dashboard.
From regional trends to innovation tracking, everything is organized in a single platform for faster, smarter decisions.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is part of Towards Healthcare Research and Consulting is a global strategy and intelligence firm focused on the biotechnology sector. We partner with biotech companies and research organizations to support innovation across drug discovery, bioprocessing, and advanced therapeutics. Through deep scientific insight and market analytics, we help accelerate development timelines, optimize R&D strategies, and translate breakthrough science into commercially viable solutions.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium